Analytical Data
-
基因名
CT83
-
简介
The CT83 protein shows specific expression in the testis, highlighting its selective presence in this reproductive organ. In addition, multiple cancer cell lines express CT83, suggesting a potential association with malignancy. CT83 Protein, Human (His, B2M) is the recombinant human-derived CT83 protein, expressed by E. coli , with N-His, B2M labeled tag.
- Application
-
别名
CT83; CXorf61; KKLC1; Kita-kyushu lung cancer antigen 1; KK-LC-1; Cancer/testis antigen 83
-
种属
Human
-
表达系统
E. coli
-
标签
N-His;B2M
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q5H943
-
表达区间
M1-T113
-
蛋白长度
Full Length
-
分子量
26.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CT83, also known as cancer/testis antigen 83, is a protein that has garnered significant attention in cancer research due to its restricted expression pattern. It is mainly found in human germ cells in the testis and is aberrantly expressed in various types of cancer, including melanoma, breast cancer, and ovarian cancer. The study of CT83 is vital for several reasons: first, its cancer/testis antigen classification makes it a potential target for immunotherapy, providing opportunities for developing cancer vaccines and personalized treatments. Second, understanding its role in tumorigenesis could unveil new molecular mechanisms underlying cancer development. Research has shown that CT83 may play a role in promoting tumor cell growth and evading immune surveillance, making it a candidate for therapeutic intervention. Moreover, as a biomarker, CT83 can potentially improve cancer diagnosis and prognosis. Thus, ongoing investigations into CT83 encompass its expression profiles, underlying biological functions, and interactions within the tumor microenvironment, contributing to a broader understanding of cancer biology and the development of targeted therapies.
